SG11202006674QA - Single-domain antibodies against lag-3 and uses thereof - Google Patents
Single-domain antibodies against lag-3 and uses thereofInfo
- Publication number
- SG11202006674QA SG11202006674QA SG11202006674QA SG11202006674QA SG11202006674QA SG 11202006674Q A SG11202006674Q A SG 11202006674QA SG 11202006674Q A SG11202006674Q A SG 11202006674QA SG 11202006674Q A SG11202006674Q A SG 11202006674QA SG 11202006674Q A SG11202006674Q A SG 11202006674QA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies against
- domain antibodies
- against lag
- lag
- domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018081356 | 2018-03-30 | ||
PCT/CN2019/080528 WO2019185040A1 (en) | 2018-03-30 | 2019-03-29 | Single-domain antibodies against lag-3 and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202006674QA true SG11202006674QA (en) | 2020-08-28 |
Family
ID=68060954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202006674QA SG11202006674QA (en) | 2018-03-30 | 2019-03-29 | Single-domain antibodies against lag-3 and uses thereof |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP3774917A4 (en) |
JP (1) | JP7346790B2 (en) |
KR (1) | KR20200138720A (en) |
CN (1) | CN111886254B (en) |
AU (1) | AU2019241350A1 (en) |
CA (1) | CA3093034A1 (en) |
IL (1) | IL276260A (en) |
SG (1) | SG11202006674QA (en) |
TW (1) | TW202003567A (en) |
WO (1) | WO2019185040A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7366908B2 (en) | 2018-01-15 | 2023-10-23 | ナンジン レジェンド バイオテック カンパニー,リミテッド | Single domain antibodies against PD-1 and variants thereof |
WO2020249071A1 (en) * | 2019-06-12 | 2020-12-17 | Nanjing GenScript Biotech Co., Ltd. | Anti-pd-l1/anti-lag-3 multiple antigen binding proteins and methods of use thereof |
US11124568B1 (en) * | 2020-08-19 | 2021-09-21 | Vitruviae LLC | CD3/CD25 antibodies for neuro-immune diseases |
WO2022109987A1 (en) * | 2020-11-27 | 2022-06-02 | Shanghai Benemae Pharmaceutical Corporation | Novel anti-lag3 antibodies and methods of making and using the same |
EP4019548A1 (en) * | 2020-12-23 | 2022-06-29 | Vrije Universiteit Brussel | Anti lag3 vhhs and their use |
KR102461837B1 (en) * | 2022-01-13 | 2022-11-01 | ㈜지아이이노베이션 | Fusion protein comprising extracellular domain of cd80 and anti-lag3 antibody fragments and use thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013201422B2 (en) * | 2012-01-23 | 2015-04-09 | Ablynx Nv | Sequences directed against hepatocyte growth factor (HFG) and polypeptides comprising the same for the treatment of cancers and/or tumors |
CN113583129A (en) * | 2014-03-14 | 2021-11-02 | 诺华股份有限公司 | Antibody molecules against LAG-3 and uses thereof |
JO3663B1 (en) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | Anti-lag3 antibodies and antigen-binding fragments |
CN104479015A (en) * | 2014-12-04 | 2015-04-01 | 东南大学 | Nano antibody aiming at NGAL epitope and application thereof |
TWI773646B (en) * | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | Lag-3-binding molecules and methods of use thereof |
WO2017015560A2 (en) * | 2015-07-22 | 2017-01-26 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind lag3 |
US20190010231A1 (en) * | 2015-08-07 | 2019-01-10 | Pieris Pharmaceuticals Gmbh | Novel fusion polypeptide specific for lag-3 and pd-1 |
DK3356401T3 (en) * | 2015-09-30 | 2020-09-07 | Igm Biosciences Inc | BINDING MOLECULES WITH MODIFIED J-CHAIN |
KR102220275B1 (en) * | 2015-11-18 | 2021-02-26 | 머크 샤프 앤드 돔 코포레이션 | Pd1 and/or lag3 binders |
WO2017087901A2 (en) * | 2015-11-19 | 2017-05-26 | Sutro Biopharma, Inc. | Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies |
CN107400166A (en) * | 2016-05-19 | 2017-11-28 | 苏州康宁杰瑞生物科技有限公司 | for CTLA4 single domain antibody and its derived protein |
WO2018014260A1 (en) * | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
WO2018068201A1 (en) * | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
-
2019
- 2019-03-29 CA CA3093034A patent/CA3093034A1/en active Pending
- 2019-03-29 EP EP19776254.5A patent/EP3774917A4/en active Pending
- 2019-03-29 WO PCT/CN2019/080528 patent/WO2019185040A1/en unknown
- 2019-03-29 SG SG11202006674QA patent/SG11202006674QA/en unknown
- 2019-03-29 CN CN201980018392.5A patent/CN111886254B/en active Active
- 2019-03-29 TW TW108111097A patent/TW202003567A/en unknown
- 2019-03-29 JP JP2020542151A patent/JP7346790B2/en active Active
- 2019-03-29 AU AU2019241350A patent/AU2019241350A1/en active Pending
- 2019-03-29 KR KR1020207025493A patent/KR20200138720A/en active Search and Examination
-
2020
- 2020-07-23 IL IL276260A patent/IL276260A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2019185040A1 (en) | 2019-10-03 |
CN111886254B (en) | 2023-12-08 |
IL276260A (en) | 2020-09-30 |
KR20200138720A (en) | 2020-12-10 |
EP3774917A4 (en) | 2022-01-19 |
US20210017279A1 (en) | 2021-01-21 |
JP7346790B2 (en) | 2023-09-20 |
EP3774917A1 (en) | 2021-02-17 |
JP2021516951A (en) | 2021-07-15 |
CN111886254A (en) | 2020-11-03 |
AU2019241350A1 (en) | 2020-07-30 |
CA3093034A1 (en) | 2019-10-03 |
TW202003567A (en) | 2020-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL275575A (en) | Single-domain antibodies and variants thereof against tigit | |
EP3652212A4 (en) | Antibodies binding lag-3 and uses thereof | |
IL275737A (en) | Antibodies and variants thereof against tigit | |
IL276950A (en) | Anti-cd73 antibodies and uses thereof | |
IL274438A (en) | Single-domain antibodies and variants thereof against pd-l1 | |
IL282968A (en) | Anti-nkg2a antibodies and uses thereof | |
IL278846A (en) | Anti-cd3 antibodies and uses thereof | |
SG11202100746WA (en) | Anti-tigit antibody and use thereof | |
IL276260A (en) | Single-domain antibodies against lag-3 and uses thereof | |
SG11202105885WA (en) | Anti-claudin antibodies and uses thereof | |
IL275740A (en) | Single-domain antibodies and variants thereof against pd-1 | |
SG11202104240TA (en) | Cll1-targeting antibody and application thereof | |
ZA202006066B (en) | Anti-hla-g antibodies and use thereof | |
IL275826A (en) | Anti-mct1 antibodies and uses thereof | |
IL281297A (en) | Anti-npr1 antibodies and uses thereof | |
SG11202009772PA (en) | Anti-dll3 antibodies and uses thereof | |
SG11202009625WA (en) | Anti-trem-1 antibodies and uses thereof | |
IL280321A (en) | Anti-cxcr2 antibodies and uses thereof | |
IL277330A (en) | Anti-il-27 antibodies and uses thereof | |
IL283875A (en) | Anti-il-27 antibodies and uses thereof | |
IL277075A (en) | Anti-phf-tau antibodies and uses thereof | |
IL276548A (en) | Bcma-binding antibodies and uses thereof | |
IL283926A (en) | Anti-alpha-synuclein antibodies and uses thereof | |
IL281202A (en) | Anti-tnfrsf9 antibodies and uses thereof | |
IL283890A (en) | Anti-periostin antibodies and uses thereof |